NCT04932980View on ClinicalTrials.gov

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

NAEnrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

March 31, 2028

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Aflibercept

administration of anti-VEGF Aflibercept (Eylea)

DRUG

Brolucizumab

administration of anti-VEGF Brolucizumab (Beovu)

PROCEDURE

early treat and extend (T&E)

extension of treatment intervals (T\&E) from the beginning of treatment

Trial Locations (1)

3007

Berner Augenklinik, Bern

All Listed Sponsors
collaborator

medignition AG

UNKNOWN

lead

Berner Augenklinik

OTHER

NCT04932980 - Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | Biotech Hunter | Biotech Hunter